Who owns PMV PHARMACEUTICALS INC?
- Ticker: PMVP
- CUSIP Number: 69353y103
Tip: Access positions for across all investors
Analyze quarterly positions in Pmv Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Pmv Pharmaceuticals stock
Who bought or sold PMV PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BML Capital Management | 5.3M | $6.6M | 1% | Mar 2026 |
|
| Tang Capital Management | 4.2M | $5.3M | -14% | Mar 2026 |
|
| Sio Capital Management | 3.1M | $3.8M | 17% | Mar 2026 |
|
| Arrowpoint Asset Management | 2.9M | $3.6M | -7% | Mar 2026 |
|
| Euclidean Capital | 2.6M | $3.3M | 0% | Mar 2026 |
|
| Eversept Partners | 2.3M | $2.9M | 100% | Mar 2026 |
|
| Acadian Asset Management | 2.2M | $2.7M | 10% | Mar 2026 |
|
| Vanguard Capital Management | 2.0M | $2.4M | 100% | Mar 2026 |
|
| Two Sigma Investments | 1.9M | $2.3M | 167% | Mar 2026 |
|
| Adage Capital Partners GP | 1.9M | $2.3M | 100% | Mar 2026 |
|
| BlackRock | 874k | $1.1M | -20% | Mar 2026 |
|
| Morgan Stanley | 864k | $1.1M | 774% | Mar 2026 |
|
| Stonepine Capital Management | 708k | $878k | -38% | Mar 2026 |
|
| Longaeva Partners | 552k | $685k | 100% | Mar 2026 |
|
| Geode Capital Management | 496k | $616k | 11% | Mar 2026 |
|
| Aldebaran Capital | 473k | $587k | -1% | Mar 2026 |
|
| Marshall Wace | 434k | $538k | -7% | Mar 2026 |
|
| Bridgeway Capital Management | 429k | $532k | 0% | Mar 2026 |
|
| Walleye Trading Advisors | 336k | $416k | 0% | Mar 2026 |
|
| Assenagon Asset Management | 330k | $442k | -9% | Jun 2026 |
|
| Vanguard Fiduciary Trust | 298k | $370k | 100% | Mar 2026 |
|
| Bank of America Corporation | 241k | $298k | 100% | Mar 2026 |
|
| ADAR1 Capital Management | 231k | $286k | 129% | Mar 2026 |
|
| State Street Corporation | 183k | $227k | 0% | Mar 2026 |
|
| Verdad Advisers | 180k | $223k | 100% | Mar 2026 |
|
| Jacobs Levy Equity Management | 180k | $223k | -66% | Mar 2026 |
|
| Rbf Capital | 162k | $201k | 0% | Mar 2026 |
|
| Evoke Wealth | 133k | $165k | 0% | Mar 2026 |
|
| Citadel Advisors | 129k | $160k | -5% | Mar 2026 |
|
| Jane Street | 124k | $154k | -75% | Mar 2026 |
|
| BIT Capital GmbH | 124k | $153k | 100% | Mar 2026 |
|
| Northern Trust | 115k | $143k | -70% | Mar 2026 |
|
| Goldman Sachs Group | 115k | $142k | -10% | Mar 2026 |
|
| Ikarian Capital | 89k | $111k | 0% | Mar 2026 |
|
| Velan Capital Investment Management | 73k | $91k | 109% | Mar 2026 |
|
| Pnc Financial Services | 68k | $85k | -7% | Mar 2026 |
|
| Rangeley Capital | 67k | $83k | 47% | Mar 2026 |
|
| Seven Fleet Capital Management | 64k | $79k | 0% | Mar 2026 |
|
| Quadrature Capital | 61k | $76k | 232% | Mar 2026 |
|
| Accurate Wealth Management | 50k | $67k | 100% | Mar 2026 |
|
| Algert Coldiron Investors | 42k | $52k | -33% | Mar 2026 |
|
| Connor, Clark & Lunn Investment Management | 33k | $40k | 100% | Mar 2026 |
|
| Hsbc Holdings | 31k | $39k | 0% | Mar 2026 |
|
| Barclays | 28k | $34k | 0% | Mar 2026 |
|
| Squarepoint Ops | 27k | $34k | 3% | Mar 2026 |
|
| Boothbay Fund Management | 27k | $34k | 0% | Mar 2026 |
|
| Vanguard Global Advisers | 22k | $27k | 100% | Mar 2026 |
|
| Point72 Asset Management | 21k | $26k | -27% | Mar 2026 |
|
| Ohio Pers | 20k | $25k | -28% | Mar 2026 |
|
| Citigroup | 19k | $24k | 100% | Mar 2026 |
|
| Pathstone Holdings | 18k | $22k | 0% | Mar 2026 |
|
| GSA Capital Partners | 15k | $19k | 100% | Mar 2026 |
|
| CI Private Wealth | 15k | $19k | 100% | Mar 2026 |
|
| Virtu Financial | 14k | $17k | 9% | Mar 2026 |
|
| Ameriprise Financial | 13k | $16k | -80% | Mar 2026 |
|
| Sand Hill Advisors | 13k | $16k | 100% | Mar 2026 |
|
| Independent Advisor Alliance | 13k | $16k | 0% | Mar 2026 |
|
| Gts Securities | 10k | $12k | 0% | Mar 2026 |
|
| Deerfield Management Company | 8.8k | $11k | 0% | Mar 2026 |
|
| Simplex Trading | 8.2k | $10k | -71% | Mar 2026 |
|
| Silver Grove Financial Group | 5.1k | $6.3k | 100% | Mar 2026 |
|
| Tower Research Capital | 1.4k | $1.7k | -65% | Mar 2026 |
|
| Jones Financial Companies, L.L | 1.0k | $1.3k | 0% | Mar 2026 |
|
| Royal Bank of Canada | 904.00 | $1.1k | 100% | Mar 2026 |
|
| Bnp Paribas Arbitrage, Snc | 539.00 | $667.982700 | 4% | Mar 2026 |
|
| UBS Group | 361.00 | $448.001000 | -67% | Mar 2026 |
|
| Group One Trading | 90.00 | $111.996000 | 100% | Mar 2026 |
|
| Caitong International Asset Management | 3.00 | $3.999900 | 100% | Mar 2026 |
|
Who sold out of Pmv Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| OrbiMed Advisors | Dec 2025 | 5.0M | $6.2M |
| Two Sigma Advisers | Dec 2025 | 874k | $1.1M |
| XTX Topco | Dec 2025 | 105k | $131k |
| Susquehanna International | Dec 2025 | 79k | $99k |
| Two Sigma Securities | Dec 2025 | 23k | $29k |
| Nine Masts Capital | Dec 2025 | 17k | $21k |